Myocet + bleomycin + vinblastine + dacarbazine

Myocet + bleomycin + vinblastine + dacarbazine is a four-drug chemotherapy combination regimen. It consists of: - Myocet (non-pegylated liposomal doxorubicin), an anthracycline antibiotic that intercalates DNA and inhibits topoisomerase II, leading to inhibition of DNA replication and cell death. - Bleomycin, a glycopeptide antibiotic that induces DNA strand breaks through free radical formation. - Vinblastine, a vinca alkaloid that inhibits microtubule assembly, disrupting mitosis. - Dacarbazine, an alkylating agent that methylates guanine in DNA, causing cytotoxicity. This combination is used as a variant of the classic ABVD regimen for Hodgkin lymphoma. The substitution of conventional doxorubicin with Myocet aims to reduce cardiotoxicity while maintaining antitumor efficacy. The regimen targets rapidly dividing cancer cells via multiple mechanisms—DNA damage (doxorubicin/Myocet and dacarbazine), microtubule disruption (vinblastine), and induction of apoptosis through oxidative stress (bleomycin). This approach may be particularly considered in patients at higher risk for cardiac or pulmonary toxicity[1][5].